ASCO 2022 Conference Coverage
Playback speed
10 seconds
ASCO 2022 Efficacy & Safety Results From the Phase 3 ASCEMBL Study of Asciminib vs. Bosutinib in CP-CML After ≥2 Prior TKIs: Week 96 Update
By
ASCO 2022 Conference Coverage
FEATURING
Jorge Cortés
By
ASCO 2022 Conference Coverage
FEATURING
Jorge Cortés
269 views
July 12, 2022
Comments 0
Login to view comments.
Click here to Login
Leukemia